Apolizumab

Drug Profile

Apolizumab

Alternative Names: Hu1D10; Monoclonal antibody SMART 1D10; Remitogen; SMART 1D10 antibody

Latest Information Update: 31 Oct 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PDL BioPharma
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-Hodgkin's lymphoma

Highest Development Phases

  • Discontinued Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 11 Sep 2003 Discontinued - Phase-I for Solid tumours in USA (unspecified route)
  • 26 Jun 2002 Discontinued - Phase-II for Non-Hodgkin's lymphoma in USA (Infusion)
  • 21 May 2002 Phase-I clinical trials in Solid tumours in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top